Benefit-Risk Analysis of Buprenorphine for Pain Management

Show simplified metadata
dc.ada.noteFor Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu
dc.creatorHale, Martin
dc.creatorGarofoli, Mark
dc.creatorRaffa, Robert B.
dc.date.accessioned2021-10-26T21:17:39Z
dc.date.available2021-10-26T21:17:39Z
dc.date.issued2021-05-24
dc.description.abstractHealth care providers in the United States are facing challenges in selecting appropriate medication for patients with acute and chronic pain in the midst of the current opioid crisis and COVID-19 pandemic. When compared with conventional opioids, the partial μ-opioid receptor agonist buprenorphine has unique pharmacologic properties that may be more desirable for pain management. The formulations of buprenorphine approved by the US Food and Drug Administration for pain management include intravenous injection, transdermal patch, and buccal film. A comparison of efficacy and safety data from studies of buprenorphine and conventional opioids suggests that buprenorphine may be a better-tolerated treatment option for many patients that provides similar or superior analgesia. Our benefit-risk assessment in this narrative review suggests that health care providers should consider that buprenorphine may be an appropriate alternative for pain management over other opioids.
dc.description.departmentPharmeceutical Sciences
dc.description.schoolcollegeTemple University. School of Pharmacy
dc.format.extent11 pages
dc.identifier.citationHale M, Garofoli M, Raffa RB. Benefit-Risk Analysis of Buprenorphine for Pain Management. J Pain Res. 2021;14:1359-1369, https://doi.org/10.2147/JPR.S305146
dc.identifier.doihttp://dx.doi.org/10.34944/dspace/7001
dc.identifier.issn1178-7090
dc.identifier.urihttp://hdl.handle.net/20.500.12613/7020
dc.languageEnglish
dc.language.isoeng
dc.relation.doihttps://doi.org/10.2147/jpr.s305146
dc.relation.haspartJournal of Pain Research, Vol. 14
dc.relation.ispartofCOVID-19 Research
dc.relation.isreferencedbyDove Medical Press
dc.rightsAttribution-NonCommercial CC BY-NC
dc.rights.urihttp://creativecommons.org/licenses/by-nc/3.0/
dc.subjectBuprenorphine
dc.subjectBuprenorphine buccal film
dc.subjectAnalgesia
dc.subjectPain
dc.subjectOpioids
dc.temple.creatorRaffa, Robert B.
dc.titleBenefit-Risk Analysis of Buprenorphine for Pain Management
dc.typeText
dc.type.genreJournal article
refterms.dateFOA2021-10-26T21:17:39Z
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Raffa-JournalArticle-2021-05.pdf
Size:
2.14 MB
Format:
Adobe Portable Document Format
Download
Collections
COVID-19 Research